Zenas files new $200M stock offering as obexelimab BLA review continues
Zenas ended its prior at-the-market stock sale and filed a new $200 million offering under the same sales agreement, while reporting Q3 results and pipeline progress toward a May 2027 PDUFA date.
SEC filing (2)